Patent application number | Description | Published |
20090136998 | LUCIFERASES AND METHODS FOR MAKING AND USING THE SAME - Briefly described, embodiments of this disclosure include polynucleotides that encode mutant | 05-28-2009 |
20090275081 | BIOTIN-LIGASE SYSTEM FOR SECRETION OF BIOTINYLATED PROTEIN - The present invention provides methods of metabolically biotinylating recombinant proteins. Cell lines and specific protein and nucleic acid constructs for use in the methods of the present invention are also provided herein. | 11-05-2009 |
20090311181 | Engineered Anti-Prostate Stem Cell Antigen (PSCA) Antibodies for Cancer Targeting - The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging. | 12-17-2009 |
20100069616 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 03-18-2010 |
20100233170 | Fully human antibodies against N-Cadherin - The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer. | 09-16-2010 |
20100272732 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 10-28-2010 |
20100297004 | HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION - The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA. | 11-25-2010 |
20110229955 | LUCIFERASES AND METHODS FOR MAKING AND USING THE SAME - Briefly described, embodiments of this disclosure include polynucleotides that encode mutant | 09-22-2011 |
20120020983 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 01-26-2012 |
20120076728 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS - This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided. | 03-29-2012 |
20120077962 | HUMANIZED ANTI-PROSTATE STEM CELL ANTIGEN MONOCLONAL ANTIBODY - Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA. | 03-29-2012 |
20120178141 | LUCIFERASES AND METHODS FOR MAKING AND USING THE SAME - Briefly described, embodiments of this disclosure include polynucleotides that encode mutant | 07-12-2012 |
20120283418 | COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF - The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions. | 11-08-2012 |
20120295326 | LUCIFERASES AND METHODS FOR MAKING AND USING THE SAME - Briefly described, embodiments of this disclosure include polynucleotides that encode mutant | 11-22-2012 |
20130230527 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 09-05-2013 |
20130344078 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 12-26-2013 |
20140017240 | Fully Human Antibodies Against N-Cadherin - The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer. | 01-16-2014 |
20140072569 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 03-13-2014 |
20150044694 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 02-12-2015 |